Hansa will apply to the EMA to convert Idefrix’s conditional approval into full marketing authorisation.

Cynata Therapeutics has received a Positive Opinion from the European Medicines Agency’s Paediatric Committee (PDCO) on its ...

HealthDay News — Having a preexisting autoimmune disease is an independent risk factor for poor outcomes with myelodysplastic syndrome (MDS), according to a study published in the June issue of ...

Detailed price information for Cynata Therapeutics Ltd (CYYNF) from The Globe and Mail including charting and trades.

Graft versus host disease (GVHD) following solid organ transplantation is a rare but often fatal complication arising when donor immune cells contained within the graft recognise recipient tissues as ...

DOTHAN, Ala. (WDHN) — Southeast Health has used funds raised during their 2025 Champions of Hope event to buy a blood irradiator, a piece of equipment that is used to treat cancer patients and ...

Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The ...

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared ...